ALKBH5

Across TCGA pan-cancer cohorts, ALKBH5 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of ALKBH5’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where ALKBH5 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ALKBH5 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

CCRCC, LSCC, and LUAD are the cancer types where ALKBH5 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ALKBH5 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	III,IV	+0.349	<.001	12	view →
LSCC	Female	All	+0.603	<.001	9	view →
LUAD	All	III,IV	+0.389	<.001	9	view →
HNSC	All	IV	+0.341	<.001	9	view →
PDAC	All	II,III,IV	−0.227	<.001	8	view →
COAD	Female	III,IV	+0.268	.037	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

ALKBH5–CCRCC

Open the CCRCC breakdown →